Fluorescent Microsatellite Analysis of Urine Sediment in Patients with Urothelial Carcinoma

被引:3
|
作者
Liang, Jian-Fang [1 ]
Zheng, Hui-Xia [1 ]
Li, Ning [1 ]
Yin, Yan [1 ]
Cheng, Cai-Xia [1 ]
Wang, Hong-Kun [1 ]
Wu, Li-Na [1 ]
Xiao, Hong [1 ]
机构
[1] Shanxi Med Univ, Affiliated Hosp 1, Dept Pathol, Taiyuan 030001, Peoples R China
关键词
Fluorescent multiplex PCR; Microsatellite analysis; Urinary sediment; Urothelial carcinoma; TRANSITIONAL-CELL CARCINOMA; BLADDER-CANCER; INSTABILITY; EXPRESSION; GENE; DNA;
D O I
10.1159/000317455
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Aims: To detect microsatellite loci alterations by fluorescent multiplex PCR in urine sediment cell of urothelial carcinoma, and to determine if they can be used as genetic markers for diagnosis of urothelial carcinoma. Materials and Methods: Microsatellite alteration analysis was conducted using fluorescent multiplex PCR with samples from 64 cases of urothelial carcinomas of the bladder. Three microsatellites spanning the 3p14 and two additional microsatellites in 9q33 and 9p22 were analyzed. Microsatellite alterations (microsatellite instability and/or loss of heterozygosity) in urine sediment cells of urothelial carcinoma patients matched for peripheral blood and tumor tissue were all analyzed. Results: The frequency of microsatellite alterations in urothelial carcinoma was chromosome 3p (D3S1234: 14.6% (7/48), D3S1300: 16.7% (8/48), D3S1313: 8.35% (4/48)); 9q (D9S242: 33.3% (16/48)), and 9p (D9S162: 27.1% (13/48)). Microsatellite alterations happened in 62.5% (40/64) of the patients when combined with all five markers. Our study showed a significant correlation between the microsatellite alteration of the five-locus panel and recurrence (p = 0.010) and smoking habit (p = 0.006). Conclusions: The results suggest that these microsatellite loci alterations may have an important role in the recurrence of urothelial carcinomas. Further studies are needed to better determine the effect of microsatellite loci alterations on prognosis. Copyright (C) 2010 S. Karger AG, Basel
引用
收藏
页码:296 / 303
页数:8
相关论文
共 50 条
  • [31] Pembrolizumab for treating advanced urothelial carcinoma in patients with impaired performance status: Analysis of a Japanese nationwide cohort
    Ito, Katsuhiro
    Kobayashi, Takashi
    Kojima, Takahiro
    Hikami, Kensuke
    Yamada, Takeshi
    Ogawa, Kosuke
    Nakamura, Kenji
    Sassa, Naoto
    Yokomizo, Akira
    Abe, Takashige
    Tsuchihashi, Kazunari
    Tatarano, Shuichi
    Inokuchi, Junichi
    Tomida, Ryotaro
    Fujiwara, Maki
    Takahashi, Atsushi
    Matsumoto, Kazumasa
    Shimizu, Kosuke
    Araki, Hiromasa
    Kurahashi, Ryoma
    Osaki, Yu
    Tashiro, Yu
    Uegaki, Masayuki
    Ogawa, Osamu
    Kitamura, Hiroshi
    Nishiyama, Hiroyuki
    CANCER MEDICINE, 2021, 10 (10): : 3188 - 3196
  • [32] Targeted therapy of patients with urothelial carcinoma
    Slavyanskaya, Tatiana
    Salnikova, Svetlana
    Avdonkina, Natalia
    Sepiashvili, Revaz
    Baldueva, Irina
    ALLERGY, ASTHMA & IMMUNOPHYSIOLOGY: INNOVATIVE TECHNOLOGIES, 2016, : 281 - 288
  • [33] High diagnostic efficacy of 5-aminolevulinic acid-induced fluorescent urine cytology for urothelial carcinoma
    Gaku Yamamichi
    Wataru Nakata
    Masaru Tani
    Go Tsujimura
    Yuichi Tsujimoto
    Mikio Nin
    Akihiro Mimura
    Hideaki Miwa
    Masao Tsujihata
    International Journal of Clinical Oncology, 2019, 24 : 1075 - 1080
  • [34] A Prospective Blinded Evaluation of Urine-DNA Testing for Detection of Urothelial Bladder Carcinoma in Patients with Gross Hematuria
    Dahmcke, Christina M.
    Steven, Kenneth E.
    Larsen, Louise K.
    Poulsen, Asger L.
    Abdul-Al, Ahmad
    Dahl, Christina
    Guldberg, Per
    EUROPEAN UROLOGY, 2016, 70 (06) : 916 - 919
  • [35] Usefulness of NMP22 as an Adjunct to a Typical Urine Cytology and Low-Grade Urothelial Carcinoma
    Arora, Vinod Kumar
    Sarungbam, Judy
    Bhatia, Arati
    Singh, Navjeevan
    Agrawal, Vivek
    Aggarwal, Seema
    DIAGNOSTIC CYTOPATHOLOGY, 2010, 38 (11) : 788 - 790
  • [36] Deletion analysis of tumor and urinary DNA to detect bladder cancer:: Urine supernatant versus urine sediment
    Szarvas, Tibor
    Kovalszky, Ilona
    Bedi, Katalin
    Szendroi, Attila
    Majoros, Attila
    Riesz, Peter
    Fuele, Tibor
    Laszlo, Viktoria
    Kiss, Andras
    Romics, Imre
    ONCOLOGY REPORTS, 2007, 18 (02) : 405 - 409
  • [37] ImmunoCyt/uCyt plus ™ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma
    Têtu, B
    Tiguert, R
    Harel, F
    Fradet, Y
    MODERN PATHOLOGY, 2005, 18 (01) : 83 - 89
  • [38] Prognostic value of prior history of urothelial carcinoma of the bladder in patients with upper urinary tract urothelial carcinoma: results from a retrospective multicenter study
    Nuhn, Philipp
    Novara, Giacomo
    Seitz, Christian
    Gupta, Amit
    Matsumoto, Kazumasa
    Kassouf, Wassim
    Walton, Thomas J.
    Fritsche, Hans-Martin
    Tritschler, Stefan
    Martinez-Salamanca, Juan I.
    Ficarra, Vincenzo
    Karakiewicz, Pierre I.
    Mazzoleni, Guido
    Shariat, Shahrokh F.
    Bastian, Patrick J.
    WORLD JOURNAL OF UROLOGY, 2015, 33 (07) : 1005 - 1013
  • [39] The current status of molecular biomarkers in patients with metastatic urothelial carcinoma of the bladder
    Kerr, Preston S.
    Freedland, Stephen J.
    Williams, Stephen B.
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2020, 20 (02) : 127 - 129
  • [40] Prognostic Utility of FBLN2 Expression in Patients With Urothelial Carcinoma
    Li, Wei-Ming
    Chan, Ti-Chun
    Huang, Steven Kuan-Hua
    Wu, Wen-Jeng
    Ke, Hung-Lung
    Liang, Peir-In
    Wei, Yu-Ching
    Shiue, Yow-Ling
    Li, Chien-Feng
    FRONTIERS IN ONCOLOGY, 2020, 10